Toxicity of Selected Cationic Drugs in Retinoblastomal Cultures and in Cocultures of Retinoblastomal and Retinal Pigment Epithelial Cell Lines

Neurochemical Research

Volumn 29, Issue 1, 2004, Pages 305-311

  Mäenpää, Hanna ^a,b   Toimela, Tarja ^a   Mannerström, Marika ^a   Saransaari, Pirjo ^a   Tähti, Hanna ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cell lines; Chloroquine; In vitro; Retinal coculture; Tamoxifen; Toremifene

Indexed keywords

CHLOROQUINE; TAMOXIFEN; TOREMIFENE;

ARTICLE; CELL VIABILITY; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NERVE CELL CULTURE; NEUROTOXICITY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINOBLASTOMA; TOXICITY TESTING;

CATIONS; CELL LINE; CELL SURVIVAL; CHLOROQUINE; COCULTURE TECHNIQUES; ESTROGEN RECEPTOR MODULATORS; HUMANS; PIGMENT EPITHELIUM OF EYE; RETINOBLASTOMA; TAMOXIFEN; TOREMIFENE;

EID: 0842301304     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NERE.0000010459.48656.4a     Document Type: Article

References (45)

1. Pavlidis, N. A., Petris, C., Briassoulis, E., Klouvas, G., Psilas, C., Rempapis, J., and Petroutsos, G. 1992. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity: A prospective study of 63 patients. Cancer 69:2961-2964.
2. Buzdar, A. U. and Hortobagyi, G. N. 1998. Tamoxifen and toremifene in breast cancer: Comparison of safety and efficacy. J. Clin. Oncol. 16:348-353.
3. Williams, G. M. and Jeffrey, A. M. 1997. Safety assessment of tamoxifen and toremifene. Oncology (Huntingt.) 11:41-47.
4. Pukkala, E., Kyyrönen, P., Sankila, R., and Holli, K. 2002. Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: A population-based case-control study. Int. J. Cancer 100:337-341.
5. Bruinink, A., Zimmermann, G., and Riesen, F. 1991. Neurotoxic effects of chloroquine in vitro. Arch. Toxicol. 65:480-484.
6. Browning, D. J. 2002. Hydroxychloroquine and chloroquine retinopathy: Screening for drug toxicity. Am. J. Ophthalmol. 133:649-656.
7. Marmorstein, A. D., Finnemann, S. C., Bonilha, V. L., and Rodriguez-Boulan, E. 1998. Morphogenesis of the retinal pigment epithelium: Toward understanding retinal degenerative diseases. Ann. NY Acad. Sci. 857:1-12.
8. Young, R. W. and Bok, D. 1969. Participation of the retinal pigment epithelium in the rod outer segment renewal process. J. Cell Biol. 42:392-403.
9. Mannerström, M., Mäenpää, H., Toimela, T., Salminen, L., and Tähti, H. 2001. The phagocytosis of rod outer segments is inhibited by selected drugs in retinal pigment epithelial cell cultures. Pharmacol. Toxicol. 88:27-33.
10. Reid, T. W., Albert, D. M., Rabson, A. S., Russell, P., Craft, J., Chu, E. W., Tralka, T. S., and Wilcox, J. L. 1974. Characteristics of an established cell line of retinoblastoma. J. Natl. Cancer Ins.t 53:347-360.
11. Kyritsis, A. P., Tsokos, M., Triche, T. J., and Chader, G. J. 1986. Retinoblastoma: A primitive tumor with multipotential characteristics. Invest. Ophthalmol. Vis. Sci. 27:1760-1764.
12. Kyritsis, A. P., Tsokos, M., Triche, T. J., and Chader, G. J. 1984. Retinoblastoma: Origin from a primitive neuroectodermal cell? Nature 307:471-473.
13. Deng, M. H., Lopez, G., Lynch, H. J., and Wurtman, R. J. 1991. Melatonin and its precursors in Y79 human retinoblastoma cells: Effect of sodium butyrate. Brain Res. 561:274-278.
14. Dunn, K. C., Aotaki-Keen, A. E., Putkey, F. R., and Hjelmeland, L. M. 1996. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp. Eye Res. 62:155-169.
15. Bridges, C. C., Kekuda, R., Wang, H., Prasad, P. D., Mehta, P., Huang, W., Smith, S. B., and Ganapathy, V. 2001. Structure, function, and regulation of human cystine/glutamate transporter in retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 42:47-54.
16. Han, Y. H., Sweet, D. H., Hu, D. N., and Pritchard, J. B. 2001. Characterization of a novel cationic drug transporter in human retinal pigment epithelial cells. J. Pharmacol. Exp. Ther. 296:450-457.
17. Gretzer, C., Thomsen, P., Jansson, S., and Nilsson, M. 2000. Coculture of human monocytes and thyrocytes in bicameral chamber: Monocyte-derived IL-1α impairs the thyroid epithelial barrier. Cytokine 12:32-40.
18. Cestelli, A., Catania, C., Agostino, S., Di Liegro, I., Licata, L., Schiera, G., Pitarresi, G. L., Savettieri, G., De, C., Giandalia, G., and Giannola, L. I. 2001. Functional feature of a novel model of blood brain barrier: Studies on permeation of test compounds. J. Control Release 76:139-147.
19. Mäenpää, H., Mannerström, M., Toimela, T., Salminen, L., Saransaari, P., and Tähti, H. 2002. Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells. Pharmacol. Toxicol. 91:116-122.
20. Mannerström, M., Zorn-Kruppa, M., K., Diehl, H., Engelke, M., Toimela, T., Mätenpää, H., Huhtala, A., Uusitalo, H., Salminen, L., Pappas, P., Marselos, M., Mäntylä, M., Mäntylä, E., and Tähti, H. 2002. Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells. Toxicol. In Vitro 16:193-200.
21. Schneider, P. 1992. Drug-induced lysosomal disorders in laboratory animals: new substances acting on lysosomes. Arch. Toxicol. 66:23-33.
22. Toimela, T., Salminen, L., and Tähti, H. 1998. Effects of tamoxifen, toremifene and chloroquine on the lysosomal enzymes in cultured retinal pigment epithelial cells. Pharmacol. Toxicol. 83:246-251.
23. Lu, X., Errington, J., Chen, V. J., Curtin, N. J., Boddy, A. V., and Newell, D. R. 2000. Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines. Clin. Cancer Res. 6:271-277.
24. Lien, E. A., Solheim, E., and Ueland, P. M. 1991. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 51:4837-4844.
25. Trump, D. L., Smith, D. C., Ellis, P. G., Rogers, M. P., Schold, S. C., Winer, E. P., Panella, T. J., Jordan, V. C., and Fine, R. L. 1992. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J. Natl. Cancer Inst. 84:1811-1816.
26. Anttila, M., Valavaara, R., Kivinen, S., and Mäenpää, J. 1990. Pharmacokinetics of toremifene. J. Steroid Biochem. 36:249-252.
27. Flaxel, C. J., Mulholland, B., Haynes, B., and Gregor, Z. J. 2000. Intraocular penetration of tamoxifen. Ophthalmology 107:2006-2009.
28. Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R., and Williams, G. M. 1993. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res. 53:4534-4541.
29. Hirsimäki, P., Aaltonen, A., and Mäntylä, E. 2002. Toxicity of antiestrogens. Breast J. 8:92-96.
30. Karlsson, S., Hirsimäki, Y., Mäntylä, E., Nieminen, L., Kangas, L., Hirsimäki, P., Perry, C. J., Mulhem, M., Millar, P., Handa, J., and Williams, G. M. 1996. A two-year dietary carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats. Drug Chem. Toxicol. 19:245-266.
31. Jordan, V. C. 1998. Designer estrogens. Sci. Am. 279:60-67.
32. Clarke, R., Leonessa, F., Welch, J. N., and Skaar, T. C. 2001. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev. 53:25-71.
33. Croxtall, J. D., Emmas, C., White, J. O., Choudhary, Q., and Flower, R. J. 1994. Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells. Biochem. Pharmacol. 47:197-202.
34. Ogueta, S. B., Schwartz, S. D., Yamashita, C. K., and Farber, D. B. 1999. Estrogen receptor in the human eye: Influence of gender and age on gene expression. Invest. Ophthalmol. Vis. Sci. 40:1906-1911.
35. Munaut, C., Lambert, V., Noel, A., Frankenne, F., Deprez, M., Foidart, J. M., and Rakic, J. M. 2001. Presence of oestrogen receptor type beta in human retina. Br. J. Ophthalmol. 85:877-882.
36. Augustijns, P., Geusens, P., and Verbeke, N. 1992. Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis. Eur. J. Clin. Pharmacol. 42:429-433.
37. Tombran-Tink, J., Shivaram, S. M., Chader, G. J., Johnson, L. V., and Bok, D. 1995. Expression, secretion, and age-related down-regulation of pigment epithelium-derived factor, a serpin with neurotrophic activity. J. Neurosci. 15:4992-5003.
38. Tsuchiya, M., Hayasaka, S., and Mizuno, K. 1987. Affinity of ocular acid-insoluble melanin for drugs in vitro. Invest. Ophthalmol. Vis. Sci. 28:822-825.
39. Schraermeyer, U, Peters, S., Thumann, G., Kociok, N., and Heimann, K. 1999. Melanin granules of retinal pigment epithelium are connected with the lysosomal degradation pathway. Exp. Eye Res. 68:237-245.
40. Boulton, M. 1998. Melanin and the retinal pigment epithelium. Pages 68-85, in Marmor M. F. and Wolfensberger T. J. (eds.), The retinal pigment epithelium. New York: Oxford University Press.
41. Leblanc, B., Jezequel, S., Davies, T., Hanton, G., and Taradach, C. 1998. Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul. Toxicol. Pharmacol. 28:124-132.
42. Rosenthal, A. R., Kolb, H., Bergsma, D., Huxsoll, D., and Hopkins, J. L. 1978. Chloroquine retinopathy in the rhesus monkey. Invest. Ophthalmol. Vis. Sci. 17:1158-1175.
43. Fredman, P., Klinghardt, G. W., and Svennerholm, L. 1987. Effect of chloroquine on the activity of some lysosomal enzymes involved in ganglioside degradation. Biochim. Biophys. Acta 917:1-8.
44. Gaillard, P. J., Voorwinden, L. H., Nielsen, J. L., Ivanov, A., Atsumi, R., Engman, H., Ringbom, C., de Boer, A. 6., and Breimer, D. D. 2001. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur. J. Pharmac. Sci. 12:215-222.
45. Lim, I. J., Phan, T. T., Song, C., Tan, W. T., and Longaker, M. T. 2001. Investigation of the influence of keloid-derived keratinocytes on fibroblast growth and proliferation in vitro. Plast. Reconstr. Surg. 107:797-808.